Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which ...

Merck & Co’s strategy to spin off its older drugs and biosimilars into a new stand-alone business will be closely watched by other pharma companies considering the same move, analysts have said.

Merck & Co’s CEO Kenneth Frazier has said the pharma industry must take on the challenge of its poor public perception. In an interview with Yahoo Finance, Frazier defended the industry’s ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical ... of our people and exacting analysis of our research processes.

About aimed analytics aimed analytics, a pioneering company in AI-based data analytics, is enabling innovation in pharmaceutical ... collaboration with MSD/Merck for its Phase 2 study, OPTIMUS ...

Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck ...

Otsuka and Lundbeck’s Rxulti (marketed as Rexulti in the U.S.) , Merck’s Sivextro and Neurim Pharmaceutical’s Slenyto. As for withdrawals, Advanz Pharma in December took back (PDF ...

The stock currently trades near its 52-week low of $94.48, potentially presenting an opportunity as InvestingPro's Fair Value analysis ... Merck operates in a highly competitive pharmaceutical ...